<DOC>
	<DOCNO>NCT01047553</DOCNO>
	<brief_summary>This study multicentre , open , randomised , parallel-group study formoterol 9 μg one inhalation b.i.d , standard COPD therapy . Standard ( reference ) COPD treatment arm group refer safety result formoterol arm evaluate . 240 patient moderate-to-severe COPD randomise ( 120 patient formoterol-arm 120 patient standard COPD therapy ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Formoterol Daily Dose 18 µg ( 9 µg Twice Daily ) Japanese Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Outpatients , men woman ≥ 40 year A clinical diagnosis COPD accord guideline , current COPD symptom . Postbronchodilator FEV1 &lt; 80 % predict normal value FEV1/FVC &lt; 70 % , postbronchodilator A history and/or current clinical diagnosis asthma atopic diseases Allergic rhinitis Patients experience COPD exacerbation require least one follow treatment , hospitalisation and/or course systemic steroid within 4 week prior study start . Significant unstable ischaemic heart disease , arrhythmia , cardiomyopathy , heart failure , uncontrolled hypertension define investigator , relevant cardiovascular disorder judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Japanese</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Safety</keyword>
	<keyword>OT</keyword>
	<keyword>Oxis</keyword>
</DOC>